Key result
High glycemic variability linked to ~267% greater diastolic dysfunction risk in asymptomatic T2D.
Why the study?
Although T2DM is a major cause of HFpEF typically presenting as LV diastolic dysfunction, the impact of glycemic variability on LV diastolic function in these patients remains unclear.
Does high glycemic variability worsen left ventricular diastolic function in asymptomatic patients with type 2 diabetes mellitus?
Observational (n=100)
No
Does high glycemic variability worsen left ventricular diastolic function in asymptomatic patients with type 2 diabetes mellitus?
High glycemic variability is independently associated with left ventricular diastolic dysfunction in asymptomatic patients with type 2 diabetes mellitus, suggesting a potential target for HFpEF prevention.
Answers are grounded in this paper and cite their sources.
Supports further investigation of glycemic variability in diastolic dysfunction; should not yet change practice in asymptomatic type 2 diabetes.
BACKGROUND: Type 2 diabetes mellitus (T2DM) is a major cause of heart failure (HF) with preserved ejection fraction (HFpEF), usually presenting as left ventricular (LV) diastolic dysfunction. Thus, LV diastolic function should be considered a crucial marker of a preclinical form of DM-related cardiac dysfunction. However, the impact of glycemic variability (GV) on LV diastolic function in such patients remains unclear. METHODS: We studied 100 asymptomatic T2DM patients with preserved LV ejection fraction (LVEF) without coronary artery disease (age: 60 ± 14 years, female: 45%). GV was evaluated as standard deviation of blood glucose level using continuous glucose monitoring system for at least 72 consecutive hours. LV diastolic function was defined as mitral inflow E and mitral e' annular velocities (E/e'), and > 14 was determined as abnormal. RESULTS: E/e' in patients with high GV (≥ 35.9 mg/dL) was significantly higher than that in patients with low GV (11.3 ± 3.9 vs. 9.8 ± 2.8, p = 0.03) despite similar age, gender-distribution, and hemoglobin A1c (HbA1c). Multivariate logistic regression analysis showed that GV ≥ 35.9 mg/dL (odds ratio: 3.67; 95% confidence interval: 1.02-13.22; p < 0.05) was an independently associated factor, as was age, of E/e' > 14. In sequential logistic models for the associations of LV diastolic dysfunction, one model based on clinical variables including age, gender and hypertension was not improved by addition of HbA1c (p = 0.67) but was improved by addition of high GV (p = 0.04). CONCLUSION: Since HFpEF is a syndrome caused by diverse agents, reducing GV may represent a potential new therapeutic strategy for the prevention of the development of HFpEF in T2DM patients.
No takes yet. Share an insight, caveat, or question.
Yokota et al. (2019) conducted an observational in Type 2 diabetes mellitus (n=100). High glycemic variability (≥ 35.9 mg/dL) vs. Low glycemic variability (< 35.9 mg/dL) was evaluated on Left ventricular diastolic dysfunction (E/e' > 14) (OR 3.67, 95% CI 1.02-13.22, p=<0.05). High glycemic variability was independently associated with an increased risk of left ventricular diastolic dysfunction in asymptomatic patients with type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: